Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine in Transthyretin Cardiac Amyloidosis
NCT07836699Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of trimetazidine in transthyretin amyloid cardiomyopathy (ATTR-CM). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
trimetazidine
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07836699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836699.